mechlorethamine has been researched along with Lymphocytopenia in 1 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Au, L | 1 |
| Meisch, JP | 1 |
| Das, LM | 1 |
| Binko, AM | 1 |
| Boxer, RS | 1 |
| Wen, AM | 1 |
| Steinmetz, NF | 1 |
| Lu, KQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast[NCT03442088] | Phase 2 | 28 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To assess change in IL-17 in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 1.513 | -0.8315 |
To assess change in serum myeloperoxidase in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 24198 | 24294 |
To assess change in Tissue Factor in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 72.28 | 75.52 |
To assess change in in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 14.95 | 14.26 |
For each subject, we will identify a target biomarker of abnormally elevated monocytes, among 1.) intermediate, or 2.) doublets, or 3.) platelet doubles. Each subject will thus have one identified monocyte biomarker for which relative percent change will be its basis for analysis in the primary outcome measure. We will specifically assess change from baseline to 16 weeks by computing relative percent reduction for each subject being treated. Note for example that a change of 1.5% to 1.2% is (1 - (1.2/1.5))*100% = 20% reduction. The median and other summary statistics of these percent change values will be computed. Wilcoxon's signed rank test will be used to evaluate the null hypothesis of the median percent change being 0. (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Percent change (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 0.5665 | 0.1715 |
1 other study available for mechlorethamine and Lymphocytopenia
| Article | Year |
|---|---|
Suppression of Hyperactive Immune Responses Protects against Nitrogen Mustard Injury.
Topics: Animals; Bone Marrow; Calcifediol; Female; Immunity, Innate; Lymphopenia; Macrophages; Mechlorethami | 2015 |